Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.

Conclusion: Saroglitazar is safe and effective in prediabetes with dyslipidemia by exerting its dual lipid lowering and glycemic actions. PMID: 30341861 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research